Comparison · NCT02014584-d55d3658
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants With AE Related to Sexual Function in the Open-label Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants With AE Related to Sexual Function in the Open-label Treatment Period. Trial comparisons, record NCT02014584-d55d3658. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02014584-d55d3658
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0417 | 0.0115 | 0.14 | wilson | |
| Risk in group 2 | 0.0612 | 0.021 | 0.165 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0196 | -0.128 | 0.0864 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.681 | 0.119 | 3.89 | log | |
| Odds ratio, group 1 over group 2 | 0.667 | 0.106 | 4.18 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) than on Placebo (DB)/Dutasteride 0.5 mg (OL) | 51.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) | During double-blind treatment period, participants received dutasteride 0.5 mg administered orally once daily for 24 weeks. All participants completing the first 24-week treatment period continued to receive dutasteride 0.5 mg once daily for the second 24-week treatment period. | 2 | 48 | OG001 |
| Group 2 | Placebo (DB)/Dutasteride 0.5 mg (OL) | During double-blind treatment period participants received placebo administered orally once daily for 24 weeks. All participants completing the first 24-week treatment period received dutasteride 0.5 mg once daily for the second 24-week treatment period. | 3 | 49 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With AE Related to Sexual Function in the Open-label Treatment Period
- Description
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs related to sexual function are defined as: altered (decreased) libido, impotence, and ejaculation disorders.
- Time frame
- 24 weeks
- Population
- Open-Label Period Population: all participants who entered the open-label period.
Source ClinicalTrials.gov
Trial
- Title
- Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
- NCT number
- NCT02014584
- Phases
- PHASE3
- Conditions
- Alopecia
- Interventions
- Dutasteride, Placebo
- Lead sponsor
- Stiefel, a GSK Company
- Results first posted
- 2017-03-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02014584?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02014584-d55d3658